DexCom, Inc. (NASDAQ:DXCM) COO Sells $228,920.94 in Stock

DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

DexCom Trading Down 0.9 %

DXCM opened at $86.83 on Friday. The company has a market cap of $33.92 billion, a P/E ratio of 51.99, a price-to-earnings-growth ratio of 2.22 and a beta of 1.12. The company has a fifty day moving average price of $80.49 and a two-hundred day moving average price of $76.67. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Leerink Partners cut their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Wells Fargo & Company increased their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Oppenheimer cut their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $99.29.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cardinal Capital Management acquired a new stake in DexCom in the fourth quarter valued at approximately $3,459,000. Kornitzer Capital Management Inc. KS grew its position in DexCom by 45.5% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 55,752 shares of the medical device company’s stock valued at $4,336,000 after purchasing an additional 17,435 shares during the period. CIBC Asset Management Inc increased its stake in DexCom by 1.3% during the 4th quarter. CIBC Asset Management Inc now owns 125,449 shares of the medical device company’s stock valued at $9,756,000 after purchasing an additional 1,558 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in DexCom by 21.7% during the fourth quarter. Sanctuary Advisors LLC now owns 18,061 shares of the medical device company’s stock worth $1,405,000 after buying an additional 3,226 shares during the last quarter. Finally, Catalyst Capital Advisors LLC lifted its stake in shares of DexCom by 236.5% in the fourth quarter. Catalyst Capital Advisors LLC now owns 1,033 shares of the medical device company’s stock valued at $80,000 after buying an additional 726 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.